A double blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID)

Clinical and Experimental Immunology

Volumn 110, Issue 2, 1997, Pages 167-173

  Rump, J A ^a   Jahreis, A ^a   Schlesier, M ^a   Stecher, S ^a   Peter, H H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Common variable immunodeficiency; IL 2; NhuIL 2 therapy

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 2; PLACEBO;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL;

EID: 0030776087     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.tb08313.x     Document Type: Article

References (39)

1. WHO Scientific Group. Primary immunodeficiency diseases: report of a WHO Scientific Group. Immunodefic Rev 1992; 3:195-236.
2. WHO Scientific Group. Primary immunodeficiency diseases. Clin Exp Immunol 1995; 99 (Suppl. 1):10-19.
3. Webster ADB, Farrant J, Hany M, North M, Toubi E, Beattie R. Clinical and cellular features of 'common variable' hypogammaglobulinemia. J Immunol Immunopharmacol 1990; 10:14-16.
4. Saiki O, Ralph P, Cunningham-Rundles C, Good RA. Three distinct B cell defects in common variable immunodeficiency. Proc Natl Acad Sci USA 1982; 79:6008-12.
5. Saxon A, Giorgi JV, Sherr EH, Kagan JM. The failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface display. J Allergy Clin Immunol 1989; 841:44-55.
6. Farrant J, Bryant A, Almandoz F, Spickett G, Evans SW, Webster ADB. B cell function in acquired common variable hypogammaglobulinemia: proliverative responses to lymphokines. Clin Immunol Immunopathol 1989; 51:196-204.
7. Spickett GP, Webster ADB, Farrant J. Cellular abnormalities in common variable immunodeficiency. Immunodef Rev 1990; 2:199-219.
8. North ME, Spickett GP, Allsop J. Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C. Clin Exp Immunol 1991; 85:198-201.
9. Baumert E, Wolff-Vorbeck G, Schlesier M, Peter HH. Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID). Clin Exp Immunol 1992; 90:25-30.
10. Stagg AJ, Funauchi M, Knight SC, Webster ADB, Farrant J. Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol 1994; 96:48-53.
11. Fischer MB, Hauber I, Eggenbauer H et al. A defect in early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood 1994; 84:4234-41.
12. + T cells. Clin Exp Immunol 1995; 101:82-88.
13. Spickett GP, Farrant J. The role of lymphokines in common variable hypogammaglobulinemia. Immunol Today 1989; 6:192-4.
14. Pastorelli G, Roncarlo MG, Touraine JL, Peronne G, Tovo PA, De Vries JE. Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVID) produce reduced levels of interleukin 4, interleukin 2 and interferon-gamma, but proliferate normally upon activation by mitogens. Clin Exp Immunol 1989; 78:334-40.
15. Fischer MB, Hauber I, Vogel E, Wolf HM, Mannhalter JW, Eibl MM. Defective interleukin-2 and interferon-γ gene expression in response to antigen in a subgroup of patients with common variable immuno-deficiency. J Allergy Clin Immunol 1993; 92:340-52.
16. + T cell differentiation. J Clin Immunol 1993; 13:247-58.
17. Ferrer JM, Iglesias J, Hernandez M, Matamoros N. Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol 1995; 102:286-9.
18. Hauber I, Fischer MB, Maris M, Eibl MM. Reduced IL-2 expression upon antigen stimulation is accompanied by deficient IL9 gene expression in T cells of patients with CVID. Scand J Immunol 1995; 41:215-9.
19. Rump JA, Jahreis A, Schlesier M, Dräger R, Melchers I, Peter HH. Possible role of IL2 deficiency for hypogammaglobulinemia in patients with common variable immunodeficiency. Clin Exp Immunol 1992; 89:204-10.
20. Zielen S, Bauscher P, Hofmann D, Meuer SC. Interleukin 10 and immune restoration in common variable immunodeficiency. Lancet 1993; 342:750-1.
21. Punnonen J, Kainulainen L, Ruuskanen O, Nikoskelainen J, Arvilommi H. IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency. Scand J Immunol 1997; 45:203-12.
22. North ME, Akbar A, Borthwick N, Webster ADB. Ami-CD28 enhances defective mitogen responses by mononuclear cells from patients with common variable immunodeficiency. Immunodeficiency 1993; 4:17-18.
23. North ME, Akbar AN, Borthwick N, Sagawa K, Funauchi M, Webster ADB. Co-stimulation with anti-CD28 (Kolt-2) enhance DNA synthesis by defective T-cells in common variable immunodeficiency. Clin Exp Immunol 1994; 95:204-8.
24. Fischer MB, Wolf HM, Eggenbauer H et al. The costimulatory signal CD28 is fully functional but cannot correct the impaired antigen response in T cells of patients with common variable immuno-deficiency. Clin Exp Immunol 1994; 95:209-14.
25. Moser C, Schlesier M, Dräger R, Eibel H, Peter HH. Transient CD80 expression defect in a patient with variable immunodeficiency and cyclic neutropenia. Int Arch Allergy Immunol 1997; 112:96-99.
26. Farrington M, Grosmaire LS, Nonoyama S et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994; 91:1099-103.
27. Nonoyama S, Farrington ML, Ochs HD. Effect on immunoglobulin production by anti-CD40-activated human B cells: synergistic effect with IL-10 and antagonistic effect with IL-4. Clin Immunol Immunopathol 1994; 72:373-9.
28. Thon V, Eggenbauer H, Wolf HM, Fischer MB, Litzmann J, Lokaj J, Eibl MM. Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired. Clin Exp Immunol 1997; 108:1-8.
29. Bryant A, Calver NC, Toubi E, Webster ADB, Farrant J. Classification of patients with common variable immuno-deficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin Immunol Immunopathol 1990; 56:239-48.
30. Smith KA. Interleukin-2: inception impact and implications. Science 1988; 240:1169-76.
31. Paul WE. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell 1989; 57:521-4.
32. Riegel JS, Corthesy B, Flanagan WM, Crabtree GR. Regulation of the interleukin-2 gene. In: Kichimoto T, ed. Interleukins: molecular biology and immunology. Basel: Karger-Verlag. Chem Immunol 1992; 51:266-98.
33. Nonoyama S, Farrington M, Ishida H, Howard M, Ochs HD. Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin. J Clin Invest 1993; 92:1282-7.
34. Meuer SC, Dumann H, Meyer zum Büschelfelde KH, Kohler H. Low dose interleukin 2 induces systemic immune responses against HbsAg in immunodeficient non responders to hepatitis B vaccination. Lancet 1989; 1:15-17.
35. Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L. Restoration of immunoglobulin secretion in vitro in common variable immuno-deficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin Immunol Immunopathol 1992; 64:46-56.
36. Cunningham-Rundles C, Kasbay K, Mayer L. Potential use of polyethyleneglycol conjugated recombinant IL-2 in common variable immunodeficiency. Immunodeficiency 1993; 4:31-36.
37. Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethyleneglycol conjugated interleukin-2. N Engl J Med 1994; 331:918-21.
38. Wallays G, Ceuppens JL. Ligation of leucocyte function-associated (LFA) molecule-1 provides an accessory signal for T-cell activation with pokeweed mitogen. Scand J Immunol 1994; 39:137-43.
39. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989; 9:22-33.